Terhoeven P, Seybold J, Utz K, Nickel F, Lee DH, Linker R (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 419
Article Number: 117169
DOI: 10.1016/j.jns.2020.117169
Intravenous immunoglobulins (IVIg) represent an established cornerstone for the immunotherapy of chronic inflammatory demyelinating polyneuropathy (CIDP). Efficacy of IVIg for CIDP was proven in a large phase III trial. Yet, data on longer-term efficacy and effects in distinct subgroups are scarce. Our trial investigates the long-term efficacy of IVIg treatment in CIDP patients. In this observational real-world study, we retrospectively analyzed 49 CIDP patients receiving continuous IVIg treatment with a mean initial dosage of 87 g (1 g/kg body weight) every 4 weeks over a mean time of 45 months between 2010 and 2018. INCAT-Scores before the start of treatment and at the end of the observation period were compared. Over the observation period, IVIg treatment led to a median improvement of one INCAT score point. Subgroup analyses revealed a more pronounced improvement of INCAT scores in female CIDP patients, individuals with relapsing disease courses, patients with more pronounced motor impairment (higher initial INCAT scores) and in the cohort without need for concomitant other immunotherapies. These data argue for sustained beneficial effects of longer-term immunotherapy with IVIg in CIDP, particularly in females and relapsing disease forms with higher disease activity.
APA:
Terhoeven, P., Seybold, J., Utz, K., Nickel, F., Lee, D.-H., & Linker, R. (2020). Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits? Journal of the Neurological Sciences, 419. https://dx.doi.org/10.1016/j.jns.2020.117169
MLA:
Terhoeven, Pauline, et al. "Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?" Journal of the Neurological Sciences 419 (2020).
BibTeX: Download